New Alert: Arch Therapeutics, Inc (ARTH)
Traders,
Let’s keep our winning streak alive today with our newest bounce play, Arch Therapeutics, Inc (ARTH).
Before we get into the details, let’s recap some of our recent alerts:
– MXAM (realistic) 50% one day gains
– EPAZ 40% intra-day gains
– PTOG easy 150% intra-day gains
– BYSD amazing 350% intra-day gains
– IWEB 20% one day gains, 75% multi-day gains
Folks, we expect ARTH to help us continue our winning ways with a strong bounce on this oversold chart.
Having closed at $0.46 yesterday, ARTH has been beaten down recently, falling from its recent highs of $1.36.
With an RSI of just 41, a MACD turning bullish, and a reversal candle just two days ago,
technically speaking, ARTH is due for a bounce.
Arch
Therapeutics, Inc. (Arch) is a medical device company offering an
innovative, elegant, and superior approach to the rapid cessation of
bleeding (hemostasis*) and control of fluid leakage (sealant) during
surgery and trauma care. The underlying technology, exclusively licensed
from a leading university, supports an innovative platform of smart
materials that fulfill the criteria as a solution for a specialized
field we call, "stasis and barrier applications."
Physicians, industry and patients could benefit greatly from a
universal sealant for the challenges presented when an opening is
created in the body, whether via surgery, trauma, colonoscopy biopsy,
device implantation, or in a variety of consumer settings. The surgeon
must manage and preferably prevent bleeding and leakage, as well as
other challenges. Currently available tools designed to resolve these
problems are often inadequate.
Arch intends to transform the landscape of interventional healthcare
with products to seal and protect leaking and bleeding tissue. Arch’s
solution elegantly controls the movement of these fluids and substances.
Arch’s products are currently progressing in preclinical development.
The first product, AC5(TM), is designed to achieve hemostasis in minimally
invasive (laparoscopic**) and open surgical procedures.
**Laparoscopic surgery, also called minimally
invasive surgery (MIS), or keyhole surgery, is a modern surgical
technique in which operations are performed through small incisions
(usually 0.5-1.5 cm) as opposed to the larger incisions needed in open
surgery. Keyhole surgery makes use of images displayed on TV monitors to
magnify the surgical elements.
Surgeons would deem the product a "must have" because of its tremendous
features, making it very different and far advanced compared to
anything currently on the market.
AC5(TM) stops bleeding promptly. Unlike many competitive products, it
conforms to irregular wound geometry, allows for normal healing, and
helps maintain a clear field of vision directly into the wound area.
Because it is not sticky or glue-like, it is ideal for use in the
laparoscopic setting – a challenge for much of the competition.
Furthermore, it is transparent, enabling a surgeon to operate through it
in order to prophylactically stop bleeding as it starts – an important
advancement we have branded as Crystal Clear Surgery(TM).
Most importantly, time to hemostasis (TTH) for AC5(TM) is typically
measured in seconds, rather than the many minutes as provided by much of
the competition.
In preclinical tests, AC5(TM) has been simple, effective, and versatile.
To date, biocompatibility has been excellent and healing of tissue
treated with the device has been normal. This extraordinary concept, if
successfully proven clinically, could eventually lead to product
adoption available in every surgical setting across the globe.
– See more at: http://www.archtherapeutics.com/company/about-arch-therapeutics#sthash.IlS4gyB1.dpuf
Arch
Therapeutics, Inc. (Arch) is a medical device company offering an
innovative, elegant, and superior approach to the rapid cessation of
bleeding (hemostasis*) and control of fluid leakage (sealant) during
surgery and trauma care. The underlying technology, exclusively licensed
from a leading university, supports an innovative platform of smart
materials that fulfill the criteria as a solution for a specialized
field we call, "stasis and barrier applications."
Physicians, industry and patients could benefit greatly from a
universal sealant for the challenges presented when an opening is
created in the body, whether via surgery, trauma, colonoscopy biopsy,
device implantation, or in a variety of consumer settings. The surgeon
must manage and preferably prevent bleeding and leakage, as well as
other challenges. Currently available tools designed to resolve these
problems are often inadequate.
Arch intends to transform the landscape of interventional healthcare
with products to seal and protect leaking and bleeding tissue. Arch’s
solution elegantly controls the movement of these fluids and substances.
Arch’s products are currently progressing in preclinical development.
The first product, AC5(TM), is designed to achieve hemostasis in minimally
invasive (laparoscopic**) and open surgical procedures.
**Laparoscopic surgery, also called minimally
invasive surgery (MIS), or keyhole surgery, is a modern surgical
technique in which operations are performed through small incisions
(usually 0.5-1.5 cm) as opposed to the larger incisions needed in open
surgery. Keyhole surgery makes use of images displayed on TV monitors to
magnify the surgical elements.
Surgeons would deem the product a "must have" because of its tremendous
features, making it very different and far advanced compared to
anything currently on the market.
AC5(TM) stops bleeding promptly. Unlike many competitive products, it
conforms to irregular wound geometry, allows for normal healing, and
helps maintain a clear field of vision directly into the wound area.
Because it is not sticky or glue-like, it is ideal for use in the
laparoscopic setting – a challenge for much of the competition.
Furthermore, it is transparent, enabling a surgeon to operate through it
in order to prophylactically stop bleeding as it starts – an important
advancement we have branded as Crystal Clear Surgery(TM).
Most importantly, time to hemostasis (TTH) for AC5(TM) is typically
measured in seconds, rather than the many minutes as provided by much of
the competition.
In preclinical tests, AC5(TM) has been simple, effective, and versatile.
To date, biocompatibility has been excellent and healing of tissue
treated with the device has been normal. This extraordinary concept, if
successfully proven clinically, could eventually lead to product
adoption available in every surgical setting across the globe.
– See more at: http://www.archtherapeutics.com/company/about-arch-therapeutics#sthash.IlS4gyB1.dpuf
ARTH is not just a ticker and a chart. It is a growth oriented medical device company
with an amazing pipeline of products that are cruising through
preclinical trials with flying colors (according to information
extracted from their website).
Arch Therapeutics, Inc. (ARTH) is a medical
device company offering an innovative, elegant, and superior approach to
the rapid cessation of bleeding (hemostasis) and control of fluid
leakage (sealant) during surgery and trauma care. The underlying
technology, exclusively licensed from a leading university, supports an
innovative platform of smart materials that fulfill the criteria as a
solution for a specialized field we call, "stasis and barrier
applications."
Physicians, industry and patients could benefit greatly from a
universal sealant for the challenges presented when an opening is
created in the body, whether via surgery, trauma, colonoscopy biopsy,
device implantation, or in a variety of consumer settings. The surgeon
must manage and preferably prevent bleeding and leakage, as well as
other challenges. Currently available tools designed to resolve these
problems are often inadequate.
Revolutionary Technology
Arch intends to transform the landscape of interventional healthcare
with products to seal and protect leaking and bleeding tissue. Arch’s
solution elegantly controls the movement of these fluids and substances.
Arch’s products are currently progressing in preclinical development. The first product, AC5(TM), is designed to achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures.
**Laparoscopic surgery, also called minimally invasive surgery
(MIS), or keyhole surgery, is a modern surgical technique in which
operations are performed through small incisions (usually 0.5-1.5 cm) as
opposed to the larger incisions needed in open surgery. Keyhole surgery
makes use of images displayed on TV monitors to magnify the surgical
elements.
Huge Market Opportunity for ARTH
Surgeons would deem the product a "must have"
because of its tremendous features, making it very different and far
advanced compared to anything currently on the market.
AC5(TM) stops bleeding promptly. Unlike many competitive
products, it conforms to irregular wound geometry, allows for normal
healing, and helps maintain a clear field of vision directly into the
wound area.
Because it is not sticky or glue-like, it is ideal for use in the
laparoscopic setting – a challenge for much of the competition.
Furthermore, it is transparent, enabling a surgeon to operate through it
in order to prophylactically stop bleeding as it starts – an important
advancement we have branded as Crystal Clear Surgery(TM).
Most importantly, time to hemostasis (TTH) for AC5(TM) is typically measured in seconds, rather than the many minutes as provided by much of the competition.
The AC5 Difference
In preclinical tests, AC5(TM) has
been simple, effective, and versatile. To date, biocompatibility has
been excellent and healing of tissue treated with the device has been
normal. This extraordinary concept, if successfully proven clinically,
could eventually lead to product adoption available in every surgical
setting across the globe.
This corporate update provides exciting
information on the progress of the company’s development of AC5 and its
proposed future activities.
I think ARTH gives us the perfect opportunity for gains
today. Look at its technical’s the obvious magnet is its 50 day moving
average of $0.74, although a move of this size might take more than one
day.
Then again, a 60% gain may not be out of the question based on our last few alerts.
Despite yesterday’s pull back, the market is
still running hot folks. It’s time to take advantage of it and book some
real winners.
And as always, I’ll keep you up to date with any news that comes our way on ARTH.
The Team
PennyStockGeneral.com
Click Below to Join Our Social Media Networks
|
|
Normal
0
false
false
false
EN-AU
X-NONE
X-NONE
————————————————————————————- DISCLAIMER —————————————————————————————
Never invest in any stock featured on our site or emails unless you can afford
to lose your entire investment.
Full disclaimer can be read at
http://pennystockgeneral.com/disclaimer-2/
Pennystockgeneral.com employees are not registered as an Investment Adviser in
any jurisdiction whatsoever.
The disclaimer is to be read and fully understood before using our site, or
joining our email list.
None of the materials or advertisements herein constitute offers or
solicitations to purchase or sell securities of the companies profiled herein
and any decision to invest in any such company or other financial decisions
should not be made based upon the information provide herein. Instead pennystockgeneral.com strongly urges
you conduct a complete and independent investigation of the respective
companies and consideration of all pertinent risks. Pennystockgeneral.com does not offer such advice or analysis, and pennystockgeneral.com further urges
you to consult your own independent tax, business, financial and investment
advisors. Investing in micro-cap and growth securities is highly speculative
and carries and extremely high degree of risk. It is possible that an
investor’s investment may be lost or impaired due to the speculative nature of
the companies profiled.
Any statements that express or involve discussions with respect to predictions,
expectations, beliefs, plans, projections, objectives, goals, assumptions or
future events or performance are not statements of historical fact may be
"forward looking statements". Forward looking statements are based on
expectations, estimates, and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through use of
words such as "projects", "foresee", "expects",
"will", "anticipates", "estimates",
"believes", "understands", or that by statements indicating
certain actions "may", "could", or "might" occur.
Understand there is no guarantee past performance will be indicative of future
results.
In preparing this publication, pennystockgeneral.com
has relied upon information supplied by its customers, and press releases which
it believes to be reliable; however, such reliability cannot be guaranteed.
Investors should not rely on the information contained in this website. Rather,
investors should use the information contained in this website as a starting
point for doing additional independent research on the featured companies. The
advertisements in this website are believed to be reliable, however, pennystockgeneral.com and its owners,
affiliates, subsidiaries, officers, directors, representatives and agents
disclaim any liability as to the completeness or accuracy of the information
contained in any advertisement and for any omissions of materials facts from
such advertisement. Pennystockgeneral.com
is not responsible for any claims made by the companies advertised herein.
Pennystockgeneral.com may
receive compensation and its employees and affiliates may own stock that they
have purchased in the open market either prior, during, or after the release of
the companies profile which is an inherent conflict of interest in pennystockgeneral.com statements and
opinions and such statements and opinions cannot be considered independent. Pennystockgeneral.com and its
management may benefit from any increase in the share price of the profiled
companies and hold the right to sell the shares bought at any given time
including shortly after the release of the companies profile. PSG has been
compensated up to two thousand dollars for this one day profile of ARTH
by a third party, Microcap Innovations. PSG has previously been
compensated for profiles of MXAM, EPAZ, PTOG, BYSD and IWEB. Refer to
the individual emails for details of compensation.
Pennystockgeneral.com
may on occasion accept compensation in free-trading shares for it’s marketing
services of the company being profiled, and the third party that might have
compensated pennystockgeneral.com
may hold free-trading shares of the company being profiled and could very well
be selling shares of the companies stock at the same time the profile is being
disseminated to potential investors; this should be viewed as a definite
conflict of interest and as such, the reader should take this into
consideration. If Pennystockgeneral.com
ever accepts compensation in the form of free trading shares of the company
being profiled and decides to sell these shares into the public market at any
time before, during, or after the release of the companies profile our
disclaimer will be updated accordingly reflecting the current position of those
free trading shares received as compensation for our services.
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-qformat:yes;
mso-style-parent:"";
mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
mso-para-margin-top:0cm;
mso-para-margin-right:0cm;
mso-para-margin-bottom:10.0pt;
mso-para-margin-left:0cm;
line-height:115%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:"Calibri","sans-serif";
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-fareast-font-family:"Times New Roman";
mso-fareast-theme-font:minor-fareast;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:minor-bidi;} |
